Innate Pharma (IPHA) Return on Capital Employed (2021 - 2025)
Innate Pharma's (IPHA) quarterly Return on Capital Employed came in at 377.03% in Q4 2025, down 28618.0% YoY from N/an in Q4 2024, and down 138.41% on a QoQ basis from 158.15% in Q2 2025.
Innate Pharma (IPHA) Return on Capital Employed (2021 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 5 years of Return on Capital Employed data on file, last reported at 377.03% in Q4 2025.
- Quarterly Return on Capital Employed fell 28618.0% year-over-year to 377.03% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 377.03% (down 28618.0% YoY) and the FY2025 annual result came in at 118.21%, down 7164.0% from the prior year.
- Return on Capital Employed eased to 377.03% in Q4 2025, from 158.15% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 26.47% in Q2 2021 to a low of 377.03% in Q4 2025.
- A 5-year average of 100.62% and a median of 53.15% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 1933 bps — and 2025, when it tumbled 28618 bps.
- Tracing IPHA's Return on Capital Employed over 5 years: stood at 46.68% in 2021, then fell by 14 bps to 53.15% in 2022, then gained by 4 bps to 51.27% in 2023, then plunged by 77 bps to 90.85% in 2024, then sank by 315 bps to 377.03% in 2025.
- The last three Return on Capital Employed figures came in at 377.03% (Q4 2025), 158.15% (Q2 2025), and 90.85% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -377.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -377.03% |
| Jun 30, 2025 | -158.15% |
| Dec 31, 2024 | -90.85% |
| Jun 30, 2024 | -41.33% |
| Dec 31, 2023 | -51.27% |
| Jun 30, 2023 | -60.66% |
| Dec 31, 2022 | -53.15% |
| Dec 31, 2021 | -46.68% |
| Jun 30, 2021 | -26.47% |